Application of metformin in the treatment of non-diabetic diseases

国际生物医学工程杂志 Pub Date : 2019-04-28 DOI:10.3760/CMA.J.ISSN.1673-4181.2019.02.014

Xiong Yang, Neng An, Rui Yang, Jie Li, Qi-duo Shi

{"title":"Application of metformin in the treatment of non-diabetic diseases","authors":"Xiong Yang, Neng An, Rui Yang, Jie Li, Qi-duo Shi","doi":"10.3760/CMA.J.ISSN.1673-4181.2019.02.014","DOIUrl":null,"url":null,"abstract":"Metformin is currently the first-line drug for the treatment of type 2 diabetes, and it is the most widely used oral hypoglycemic drug in the world. In addition to its significant hypoglycemic effect, metformin also has potential therapeutic effects on diseases such as tumors, obesity, thyroid diseases, polycystic ovarian diseases and cardiovascular diseases. However, the specific mechanism of action of metformin is still unclear. A large number of studies have shown that the regulation of energy metabolism by metformin is not only the core of its mechanism of action in the treatment of type 2 diabetes, but also an important mechanism for its therapeutic effects in diseases such as tumors and cardiovascular diseases. In this paper, the clinical application and related drug mechanisms of metformin in the treatment of non-diabetic diseases were summarized, so as to provide reference for the majority of medical workers, and look forward to a more in-depth exploration of its drug mechanism and clinical application in the future. \n \n \nKey words: \nMetformin; Tumor therapy; Mechanism; AMPK","PeriodicalId":61751,"journal":{"name":"国际生物医学工程杂志","volume":"42 1","pages":"166-170"},"PeriodicalIF":0.0000,"publicationDate":"2019-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"国际生物医学工程杂志","FirstCategoryId":"1087","ListUrlMain":"https://doi.org/10.3760/CMA.J.ISSN.1673-4181.2019.02.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 1

Abstract

Metformin is currently the first-line drug for the treatment of type 2 diabetes, and it is the most widely used oral hypoglycemic drug in the world. In addition to its significant hypoglycemic effect, metformin also has potential therapeutic effects on diseases such as tumors, obesity, thyroid diseases, polycystic ovarian diseases and cardiovascular diseases. However, the specific mechanism of action of metformin is still unclear. A large number of studies have shown that the regulation of energy metabolism by metformin is not only the core of its mechanism of action in the treatment of type 2 diabetes, but also an important mechanism for its therapeutic effects in diseases such as tumors and cardiovascular diseases. In this paper, the clinical application and related drug mechanisms of metformin in the treatment of non-diabetic diseases were summarized, so as to provide reference for the majority of medical workers, and look forward to a more in-depth exploration of its drug mechanism and clinical application in the future. Key words: Metformin; Tumor therapy; Mechanism; AMPK

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

二甲双胍在非糖尿病疾病治疗中的应用

二甲双胍是目前治疗2型糖尿病的一线药物，也是世界上应用最广泛的口服降糖药。二甲双胍除了具有显著的降血糖作用外，对肿瘤、肥胖、甲状腺疾病、多囊卵巢疾病和心血管疾病等疾病也有潜在的治疗作用。然而，二甲双胍的具体作用机制尚不清楚。大量研究表明，二甲双胍对能量代谢的调节不仅是其治疗2型糖尿病作用机制的核心，也是其治疗肿瘤和心血管疾病等疾病的重要机制。本文对二甲双胍在治疗非糖尿病疾病中的临床应用及相关药物机制进行了综述，以期为广大医务工作者提供参考，并期待未来对其药物机制及临床应用进行更深入的探索。关键词：二甲双胍；肿瘤治疗；机制；AMPK

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊